Table 2. The general information distinguished by ITGAM expression and the characteristics of AML patients.
| General information | ITGAM | |
| Positive (N = 46) | Negative (N = 133) | |
| Age | 46.78 ± 16.99 | 46.62 ± 15.43 |
| Gender | Female (19, 41.30%) Male (27, 58.70%) | Female (72, 54.14%) Male (61, 45.86%) |
| Race | Han (31, 67.39%) Uyghur (15, 32.61%) | Han (102, 76.69%) Uyghur (31, 23.31%) |
| WBC** | 62.99 ± 71.05 | 34.81 ± 59.55 |
| Hb | 81.28 ± 22.88 | 80.99 ± 22.80 |
| PLT | 58.59 ± 57.76 | 79.71 ± 153.08 |
| Diagnosis | ||
| M1 | 4 (8.70%) | 7 (5.26%) |
| M2*** | 18 (39.13%) | 100 (75.19%) |
| M4 | 8 (17.39%)- | 10 (7.52%) |
| M5** | 16 (34.78%) | 15 (11.28%) |
| M6 | – | 1 (0.75%) |
| Prognostic generate | ||
| WT-1 | 33 (71.74%) | 94 (70.68%) |
| ASXL1 | 13 (28.26%) | 25 (18.80%) |
| TET-2 | 11 (23.91%) | 22 (16.54%) |
| DNMT3A | 6 (13.04%) | 13 (9.77%) |
| CEBPA | 4 (8.70%) | 12 (9.02%) |
| TP53 | 6 (13.04%) | 5 (3.76%) |
| NPM1 | 4 (8.70%) | 15 (11.28%) |
| FLT3 | 4 (8.70%) | 13 (9.77%) |
| IDH1/IDH2 | 0/3 (6.52%) | 3 (2.26%)/2 (1.50%) |
| C-kit | 3 (6.52%) | 10 (7.52%) |
| RUNX1 | 2 (4.35%) | 3 (2.26%) |
| NRAS | 2 (4.35%) | 3 (2.26%) |
| Regimens | ||
| Un-Treatment | 8 (17.39%) | 11 (8.15%) |
| IA | 23 (50.00%) | 73 (54.89%) |
| DA | 9 (19.57%) | 38 (28.57%) |
| CAG | 4 (8.70%) | 3 (2.22%) |
| HMAs | 2 (4.35%) | 8 (5.93%) |
| Treatment outcomes | (N = 38) | (N = 122) |
| CR* | 20 (52.63%) | 90 (73.77%) |
| PR | 4 (10.53%) | 5 (4.10%) |
| NR | 8 (21.05%) | 21 (17.21%) |
| Death | 6 (15.79%) | 6 (4.92%) |
***P < 0.001; **P < 0.01; *P < 0.05. Abbreviations: CR: complete remission; PR: partial remission; NR: no response; WBC: white blood cells; Hb: hemoglobin; PLT: platelet; IA: idarubicin, cytarabine; DA: daunorubicin, cytarabine; CAG: cytarabine, aclacinomycin, and granulocyte colony-stimulating factor; HMAs: hypomethylating agents mainly contain azacytidine or decitabine.